JP2012516348A5 - - Google Patents

Download PDF

Info

Publication number
JP2012516348A5
JP2012516348A5 JP2011548294A JP2011548294A JP2012516348A5 JP 2012516348 A5 JP2012516348 A5 JP 2012516348A5 JP 2011548294 A JP2011548294 A JP 2011548294A JP 2011548294 A JP2011548294 A JP 2011548294A JP 2012516348 A5 JP2012516348 A5 JP 2012516348A5
Authority
JP
Japan
Prior art keywords
treatment
anxiety
sleep disorder
composition
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011548294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012516348A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/022402 external-priority patent/WO2010088385A1/en
Publication of JP2012516348A publication Critical patent/JP2012516348A/ja
Publication of JP2012516348A5 publication Critical patent/JP2012516348A5/ja
Pending legal-status Critical Current

Links

JP2011548294A 2009-01-30 2010-01-28 ６−（５−クロロ−２−ピリジル）−５−［（４−メチル−１−ピペラジニル）カルボニルオキシ］−７−オキソ−６，７−ジヒドロ−５Ｈ−ピロロ［３，４−ｂ］ピラジンの被覆錠剤及びコーティングの効果を測定する方法 Pending JP2012516348A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14862109P 2009-01-30 2009-01-30
US61/148,621 2009-01-30
PCT/US2010/022402 WO2010088385A1 (en) 2009-01-30 2010-01-28 Coated tablets of 6-(5-chloro-2-pyridyl) -5-[ (4-methyl-1-piperazinyl) carbonyloxy]-7-oxo-6, 7-dihydro-5h-pyrrol o [3,4-b] pyrazine and methods for measuring effectiveness of coating

Publications (2)

Publication Number Publication Date
JP2012516348A JP2012516348A (ja) 2012-07-19
JP2012516348A5 true JP2012516348A5 (enExample) 2013-02-07

Family

ID=42091495

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011548294A Pending JP2012516348A (ja) 2009-01-30 2010-01-28 ６−（５−クロロ−２−ピリジル）−５−［（４−メチル−１−ピペラジニル）カルボニルオキシ］−７−オキソ−６，７−ジヒドロ−５Ｈ−ピロロ［３，４−ｂ］ピラジンの被覆錠剤及びコーティングの効果を測定する方法

Country Status (7)

Country Link
US (2) US20100221338A1 (enExample)
EP (2) EP2391354B1 (enExample)
JP (1) JP2012516348A (enExample)
CN (2) CN102355892B (enExample)
AU (1) AU2010208240A1 (enExample)
CA (1) CA2750059C (enExample)
WO (1) WO2010088385A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212036B2 (en) 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
CA2747008C (en) * 2007-12-19 2017-12-12 Richard Hsia Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine
US8269005B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8268832B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198277B2 (en) * 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US20110009416A1 (en) * 2009-07-07 2011-01-13 Sepracor Inc. PH INDEPENDENT FORMULATIONS OF 6-(5-CHLORO-2-PYRIDYL)-5-[(4-METHYL-1-PIPERAZINYL)CARBONYLOXY]-7-OXO-6,7-DIHYDRO-5H-PYRROLO[3,4-b]PYRAZINE
CN103408967A (zh) * 2013-07-09 2013-11-27 吴江市冰心文教用品有限公司 一种天然可食用颜料
CN118069976B (zh) * 2024-03-11 2024-08-20 华中科技大学 一种老化sbs改性沥青双组分同步再生剂最佳掺量计算方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA04285A (fr) 1972-01-07 1979-12-31 Rhone Poulenc Sa Nouveaux dérivés de la pyrrolo (3,4-b) pyrazine et leur préparation.
AR208414A1 (es) 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
US4543370A (en) * 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US5098715A (en) * 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
FR2671800B1 (fr) 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
US5786357A (en) 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
AU3245593A (en) 1991-12-02 1993-06-28 Sepracor, Inc. Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US6451345B1 (en) * 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
EA200201044A1 (ru) * 2000-03-31 2003-04-24 Нюкомед Аустриа Гмбх Фармацевтическая композиция с контролируемым высвобождением, содержащая мидодрин и/или десглимидодрин
US7396542B2 (en) * 2001-12-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
CA2556870C (en) * 2004-02-18 2014-01-28 Timothy J. Barberich Dopamine-agonist combination therapy for improving sleep quality
JP4970244B2 (ja) * 2004-04-05 2012-07-04 サノビオン ファーマシューティカルズ インク エスゾピクロンを用いる治療方法
EP1811975A2 (en) * 2004-10-19 2007-08-01 The State of Oregon Acting by and Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
WO2007006003A2 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US7476737B2 (en) * 2005-09-05 2009-01-13 Dr. Reddy's Laboratories Limited Eszopiclone process
US20070098788A1 (en) * 2005-10-28 2007-05-03 Gore Subhash P Non-benzodiazepine hypnotic compositions
AR056633A1 (es) * 2005-12-07 2007-10-17 Gador Sa Composiciones farmaceuticas de agentes hipnoticos de accion corta en forma de liberacion modificada y los procedimientos para preparar dichas formulaciones
US8309104B2 (en) * 2006-03-02 2012-11-13 Watson Pharmaceuticals, Inc. Oral controlled release formulation for sedative and hypnotic agents
US8198277B2 (en) * 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8268832B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) * 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8269005B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8212036B2 (en) * 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US20090269409A1 (en) * 2008-04-24 2009-10-29 Mukesh Kumar Garg Pharmaceutical compositions comprising eszopiclone

Similar Documents

Publication Publication Date Title
JP2012516348A5 (enExample)
HUE053946T2 (hu) 4'-Fluor-nukleozidok, 4'-fluor-nukleotidok és analógjaik HCV kezelésére
JP2012045397A5 (enExample)
JP2015503422A5 (enExample)
JP2014530840A5 (enExample)
JP2015525757A5 (enExample)
EP2841092A4 (en) METHODS, COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARAIN FLUENZA VIRUS IN IMMUNE-GROWTH PATIENTS
JP2015504870A5 (enExample)
IL236356A0 (en) Use of iron citrate to treat patients with chronic kidney disease
IT1402907B1 (it) Composizioni topiche per mantenere o ripristinare l'integrita' delle mucose.
CL2014000395A1 (es) Compuestos derivados de piridazinona sustituida; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de la esquizofrenia, trastorno esquizoafectivo, trastornos cognitivos o dolor.
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
IT1395519B1 (it) Pezzo composito, nonche' impiego del pezzo composito
ZA201402907B (en) Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies
JP2015518492A5 (enExample)
EE201300007A (et) Kombineeritud ravimkoostis diabeedi ning ainevahetush„irete raviks
JP2011519825A5 (enExample)
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
JP2013538128A5 (enExample)
JP2014500291A5 (enExample)
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
HRP20171742T1 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
JP2015143162A5 (ja) 酸化グラフェン及びグラフェン
EP2861244A4 (en) TREATMENT OF SLEEP APNEA
EP2782660A4 (en) PREVENTING NITROAMINATION IN CARBON DIOXIDE ABSORPTION PROCESSES